Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 176

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 8
Chunk 176
---
 period from February 14, 2024
    through September 30,  
    For the period from January 1, 2024
    through February 13, 

    2025  
    2024  
    2025  
    2024  
    2024 

    (Successor)  
    (Successor)  
    (Successor)  
    (Successor)  
    (Predecessor) 
  
    Operating leases: 

    Operating lease cost 
    $226,880  
    $229,331  
    $685,542  
    $585,702  
    $110,885 
  
    Variable operating lease cost 
     187,730  
     177,056  
     600,334  
     441,560  
     84,401 
  
    Total lease cost 
    $414,610  
    $406,387  
    $1,285,876  
    $1,027,262  
    $195,286 

The right-of-use asset, net for the operating lease was recorded in
the condensed consolidated balance sheets as follows:

    September 30,  
    December 31, 

    2025  
    2024 

    (Successor)  
    (Successor) 
  
    Right-of-use assets, net 
    $869,538  
    $1,464,367 

The operating lease liability
for the operating lease was recorded in the condensed consolidated balance sheets as follows:

     September 30,   December 31,      2025   2024      (Successor)   (Successor)   Operating lease liabilities, current  $931,023   $876,392   Operating lease liabilities, non-current   -    699,107   Total operating lease liabilities  $931,023   $1,575,499                Weighted-average remaining lease term of operating leases (in years)   1.00    1.75   Weighted-average discount rate for operating leases   9.60%   9.60% 

14

The following table reconciles
the undiscounted future minimum lease payments under the non-cancelable operating lease with terms